Molecular Partners Announces Presentation at the Evercore ISI 4th Annual HealthCONx Conference
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced participation by CEO Patrick Amstutz, Ph.D., in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 8:00 AM EST. The presentation will be webcasted and available on the company’s website. Molecular Partners focuses on developing DARPin therapeutics for various diseases, including oncology and infectious diseases, partnering with leading pharmaceutical companies to enhance clinical and preclinical development.
- None.
- None.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on Nov 30, 2021, at 8:00 AM EST.
The webcasted presentation will be made available on the Molecular Partners website.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs
FAQ
When will the Molecular Partners AG CEO participate in the Evercore ISI HealthCONx Conference?
Where can I watch the Molecular Partners AG presentation from the HealthCONx Conference?
What is Molecular Partners AG focused on developing?
What stock symbols are associated with Molecular Partners AG?
